Metabolic management of ischaemic heart disease

The present review summarizes the available information on the effects of the three major classes of antianginal agents (nitrates, calcium and beta-blockers) on myocardial energy metabolism. It also discusses the role of some new molecules (L-carnitine, trimetazidine and ranolazine) that have been p...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 14 Suppl G; p. 2
Main Authors Chierchia, S L, Fragasso, G
Format Journal Article
LanguageEnglish
Published England 01.11.1993
Subjects
Acetanilides
Adrenergic beta-Antagonists - therapeutic use
Angina Pectoris - drug therapy
Calcium Channel Blockers - therapeutic use
Carnitine - therapeutic use
Energy Metabolism - drug effects
Humans
Myocardium - metabolism
Nitroglycerin - therapeutic use
Piperazines - therapeutic use
Ranolazine
Trimetazidine - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:The present review summarizes the available information on the effects of the three major classes of antianginal agents (nitrates, calcium and beta-blockers) on myocardial energy metabolism. It also discusses the role of some new molecules (L-carnitine, trimetazidine and ranolazine) that have been proposed as an alternative pharmacological approach for the metabolic management of cardiac ischaemic syndromes.
ISSN:0195-668X
DOI:10.1093/eurheartj/14.suppl_G.2